Neurotech completes enrolment for dry AMD & RP trials
Neurotech Pharmaceuticals has completed enrolment for three ongoing clinical studies evaluating NT-501 as a treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).
Neurotech Pharmaceuticals has completed enrolment for three ongoing clinical studies evaluating NT-501 as a treatment for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).
NT-501 is an intraocular, cell containing polymer implant designed to provide continuous, long-term release of the therapeutic protein, ciliary neurotrophic factor (CNTF), directly into the back of the eye by means of the company's proprietary Encapsulated Cell Technology (ECT).
It is being investigated in a Phase II/III trial as treatment for early RP, a Phase II/III trial in late-stage RP and a Phase II trial for the treatment of dry AMD.
